Welcome to our dedicated page for Elanco Animal Health news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health stock.
Elanco Animal Health Incorporated (NYSE: ELAN) is a global animal health company focused on products and services that prevent and treat disease in farm animals and pets. The ELAN news feed on Stock Titan aggregates company announcements, regulatory updates and other disclosures so readers can follow how Elanco’s strategy and product portfolio evolve over time.
Elanco regularly issues news on pet health innovations, including prescription products for dogs and cats. Recent press releases have covered developments in canine dermatology, such as Zenrelia tablets for control of itching and inflammation associated with skin allergies in dogs and Befrena, an injectable monoclonal antibody targeting canine allergic and atopic dermatitis. The company also reports on its Credelio and Credelio Quattro brands for parasite control in dogs and Credelio CAT for cats, including label expansions, emergency use authorizations and new indications such as protection related to Lyme disease and emerging tick species.
Investors and industry followers will also find farm animal and corporate updates, including quarterly financial results, guidance, restructuring plans and productivity initiatives like Elanco Ascend. News items describe trends in pet health and farm animal revenue, progress in innovation pipelines, changes to manufacturing and R&D footprints, and participation in major healthcare and investor conferences.
This ELAN news page helps readers track how Elanco’s innovation, portfolio and productivity strategy is reflected in product approvals, regulatory milestones, financial performance and strategic partnerships. For anyone monitoring animal health markets, veterinary therapeutics or ELAN stock, it provides a centralized view of the company’s most recent public communications.
Elanco Animal Health (NYSE: ELAN) is expanding its shared value initiative in Sub-Saharan Africa, focused on improving livestock health and sustainability for small-scale farmers. The new project, MAHABA, aims to tackle tick infestations affecting up to 98% of cattle in Uganda and 80% in Nigeria. This initiative follows the East Africa Growth Accelerator and involves partnerships with GALVmed and the Bill & Melinda Gates Foundation. Elanco's commitment aligns with its 2030 sustainability goals, enhancing food security for local communities.
Elanco Animal Health reported a full-year 2021 revenue of $4,765 million, marking a 46% increase, largely due to Bayer Animal Health product integration. Despite a 2% decline in Q4 revenue to $1,113 million, adjusted EPS rose 75% to $0.21. Guidance for 2022 anticipates revenue between $4,745 million and $4,800 million, with adjusted EPS projected at $1.18 to $1.24. Significant innovation is expected, with $120 to $160 million in innovation revenue and 7 anticipated product approvals. Cost-cutting measures, including a reduction of 380 positions, aim to improve efficiency.
Elanco Animal Health (NYSE: ELAN) has appointed Rajeev (Bobby) Modi as executive vice president of U.S. Pet Health and Global Digital Transformation, effective March 14. Modi has two decades of experience in marketing and sales, previously serving at Conagra Brands and J.M. Smucker, where he led pet portfolio transformation. His role will focus on overseeing veterinary sales, retail, e-commerce, and preparing for upcoming product launches in the pet health pipeline. CEO Jeff Simmons highlighted Modi's expertise and vision for growing Elanco's pet health business.
Elanco Animal Health (NYSE: ELAN) is set to participate in the Cowen 42nd Annual Health Care Conference on March 7, 2022. CEO Jeff Simmons will engage in a virtual fireside chat at 2:50 p.m. ET. Attendees can access a live audio webcast via the "Events and Presentations" section on Elanco's investor website. A replay will be available for 30 days.
TriRx Pharmaceutical Services has completed the acquisition of Elanco Animal Health's manufacturing facility in Speke, UK, finalizing a two-facility sale that includes a site in Shawnee, Kansas. This strategic acquisition enhances TriRx's manufacturing capabilities for both animal and human health products, adding approximately 350 employees and advanced API and biological capacities. TriRx will support Elanco's long-term supply agreement, ensuring reliable product delivery. The acquisition marks a significant step in TriRx's growth strategy as it expands its global presence in the contract development and manufacturing sector.
Summary not available.
Elanco Animal Health (NYSE: ELAN) will participate in the BofA Securities 2022 Virtual Animal Health Summit on February 24, 2022. Jeff Simmons, president and CEO, is scheduled for a virtual fireside chat at 1:35 p.m. ET. A live audio webcast will be accessible in the "Events and Presentations" section of Elanco’s investor website, with a replay available for 30 days.
Elanco Animal Health (NYSE: ELAN) will release its Q4 and full year 2021 financial results on February 24, 2022. A conference call detailing the company’s performance is scheduled for 8:00 a.m. ET that day, accessible via a live webcast on Elanco’s website. The company has a long-standing commitment to enhancing animal health and sustainability through innovative products and services, leveraging nearly 70 years of expertise in the industry.
The FDA has approved Zorbium, a new transdermal solution for managing postoperative pain in cats, marking a significant expansion of Elanco's pain management portfolio. This long-acting medication offers up to four days of postoperative pain control from a single dose, reducing the burden on pet owners for at-home medication administration. Anticipated to launch mid-year 2022, Zorbium underscores Elanco's commitment to innovation in veterinary pain relief, addressing an unmet market need.
Elanco Animal Health (NYSE: ELAN) will participate in the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022. CEO Jeff Simmons is set to present at 10:30 a.m. ET, addressing questions from analysts. A live audio webcast of the event will be accessible on Elanco's investor website, with a replay available for 30 days afterward. Elanco is dedicated to improving animal health with nearly 70 years of experience, focusing on creating value for farmers and pet owners through innovative products and services.